FIELD: biotechnology.
SUBSTANCE: invention is a liposomal pharmaceutical composition that performs directional transportation of physiologically active agents in order to increase the therapeutic activity of medicinal preparations, as well as ensuring high efficiency and stability of the active substance in the liposomes.
EFFECT: increasing the degree of incorporation of the medicinal preparation in the liposome structure, and increasing the shelf life of the liposomal preparation without substantial changing the degree of incorporation of the medicinal preparation.
7 cl, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIPOSOMAL COMPOSITION AND METHOD FOR PRODUCTION THEREOF | 2012 |
|
RU2516893C1 |
| LIPOSOMAL COMPOSITIONS CONTAINING SLIGHTLY ACIDIC DRUGS, AND THEIR USE | 2018 |
|
RU2778886C2 |
| TUMOUR TREATMENT AGENT AND KIT CONTAINING LIPOSOMAL GEMCITABINE COMPOSITION | 2016 |
|
RU2761620C2 |
| CREATING CONTROLLED RELEASE PROFILE OF DRUG SUBSTANCE USING LIPOSOMAL COMPOSITION IN AQUEOUS AND ANHYDROUS SOLUTIONS | 2014 |
|
RU2712157C2 |
| IMPROVED LIPOSOMES AND THEIR APPLICATION | 2008 |
|
RU2482837C2 |
| AGENT FOR TREATING A TUMOR AND A KIT CONTAINING A LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2738365C2 |
| METHOD FOR PRODUCING LIPID MIXTURE AND LIPOSOMAL ORAL ANTIVIRAL THERAPEUTIC AND PROPHYLACTIC AGENT USING SAID LIPID MIXTURE | 2020 |
|
RU2746320C1 |
| AGENT FOR TREATING TUMOUR AND KIT CONTAINING LIPOSOMAL COMPOSITION OF GEMCITABINE | 2016 |
|
RU2768178C2 |
| LIPOSOMAL PERORAL ANTIVIRAL TREATMENT-AND-PROPHYLACTIC AGENT ON BASIS OF HUMAN INTERFERON ALPHA | 2008 |
|
RU2361572C1 |
| LIPOSOMAL COMPOSITION | 2010 |
|
RU2476216C1 |
